Condition: Cerebral Infarction · Stenosis Artery · Sponsor: Asan Medical Center
Currently, aspirin plus clopidogrel is considered as a standard acute treatment of ischemic stroke, based on results of CHANCE and POINT trial. However, still a considerable portion of patients showed early stroke recurrence, especially in those with stroke due to large artery atherosclerosis. Cilostazol may have benefit in reducing early stroke recurrence of neurologic deterioriation. The post-hoc analysis of CSPS.com showed that use of cilostazol after 15 days of stroke was effective for preventing subsequent stroke. The effect of adding cilostazol was more effective in those with large artery atherosclerosis and those receiving clopidogrel than aspirin.
This description comes directly from the study's public registry record.
Bum Joon Kim, Professor · +82-2- 3010-3981 · bj.kim@amc.seoul.kr
Always discuss trial participation with your own doctor first.
| Asan Medical Center | Seoul, Songpa-gu, South Korea | Recruiting |
| Pusan National University Hospital | Busan, South Korea | Recruiting |
| Chungbuk National University Hospital | Cheongju-si, South Korea | Recruiting |
| Kyungpook National University Chilgok Hospital | Daegu, South Korea | Recruiting |
| Chungnam National University Hospital | Daejeon, South Korea | Recruiting |
| Eulji University Hospital | Daejeon, South Korea | Recruiting |
| Chonnam National University Hospital | Gwangju, South Korea | Recruiting |
| Seoul National University Bundang Hospital | Gyeonggi-do, South Korea | Recruiting |
| Hallym University Medical Center | Gyeonggi-do, South Korea | Recruiting |
| Hanyang University Guri Hospital | Gyeonggi-do, South Korea | Recruiting |
| Korea University Ansan Hospital | Gyeonggi-do, South Korea | Recruiting |
| Gachon University Gil Medical Center | Incheon, South Korea | Recruiting |
+ 12 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06757764